Salud financiera de hoja de balance de Panion & Bf Biotech

Salud financiera controles de criterios 5/6

Panion & Bf Biotech tiene un patrimonio de accionistas total de NT$1.9B y una deuda total de NT$637.7M, lo que sitúa su ratio deuda-patrimonio en 33.9%. Sus activos y pasivos totales son NT$3.1B y NT$1.3B respectivamente. El BAIT de Panion & Bf Biotech es de NT$208.7M, por lo que su ratio de cobertura de intereses es de 77.4. Tiene efectivo e inversiones a corto plazo que ascienden a NT$442.7M.

Información clave

33.9%

Ratio deuda-patrimonio

NT$637.65m

Deuda

Ratio de cobertura de intereses	77.4x
Efectivo	NT$442.70m
Patrimonio	NT$1.88b
Total pasivo	NT$1.26b
Activos totales	NT$3.14b

Actualizaciones recientes sobre salud financiera

Recent updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Apr 07

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Mar 03

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Feb 04

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Jan 09

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Dec 14

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NT$1.4B) de 1760 superan a sus pasivos a corto plazo (NT$1.0B).

Pasivo a largo plazo: Los activos a corto plazo de 1760 (NT$1.4B) superan a sus pasivos a largo plazo (NT$259.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (10.4%) de 1760 se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de 1760 ha crecido de 0% a 33.9% en los últimos 5 años.

Cobertura de la deuda: La deuda de 1760 está bien cubierta por el flujo de caja operativo (59.6%).

Cobertura de intereses: Los pagos de intereses de la deuda de 1760 están bien cubiertos por el BAIT (77.4x cobertura).

Salud financiera de hoja de balance de Panion & Bf Biotech

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Panion & Bf Biotech Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings released: EPS: NT$0.23 (vs NT$0.20 in 2Q 2023)

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Panion & Bf Biotech Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$1.50 per share

Panion & Bf Biotech Inc. Announces the Cash Dividend, Payable on July 10, 2024

Panion & Bf Biotech Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$0.90 (vs NT$2.13 in FY 2022)

Panion & Bf Biotech Inc., Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Panion and BF Biotech Inc. Obtains Nephoxil NDA Approval

Panion & Bf Biotech Inc. Announces Nephoxil Receives NMPA Acceptance for NDA Application Submission

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$1.88 in 2Q 2022)

Upcoming dividend of NT$2.00 per share at 1.5% yield

Panion & Bf Biotech Inc. Announces the Cash Dividend, payable on August 11, 2023

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.32 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.91 (vs NT$0.77 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.88 (vs NT$0.97 in 2Q 2021)

Upcoming dividend of NT$1.50 per share

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: NT$0.46 (vs NT$0.32 loss in 1Q 2021)

Price target increased to NT$106

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$0.77 (vs NT$0.038 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.97 (vs NT$0.099 loss in 2Q 2020)

Upcoming dividend of NT$0.70 per share

Price target increased to NT$108

First quarter 2021 earnings released: NT$0.32 loss per share (vs NT$0.009 profit in 1Q 2020)

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Full year 2020 earnings released: EPS NT$0.36 (vs NT$2.10 in FY 2019)

Panion & Bf Biotech Inc., Annual General Meeting, Jun 04, 2021

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

New 90-day low: NT$74.10

Price target lowered to NT$97.00

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

New 90-day low: NT$80.60

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

New 90-day low: NT$91.10

Third quarter 2020 earnings released: NT$0.04 loss per share

Revenue misses expectations

New 90-day low: NT$104

New 90-day low: NT$112

Price target raised to NT$141

First half earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera